Novanta reported strong third quarter results, achieving the high end of the guidance range, and demonstrated solid bookings growth. However, challenges remain in the precision medicine and manufacturing segment, and the fourth quarter revenue guidance has been revised down due to customer and market dynamics. The company is optimistic about returning to organic growth in 2025, despite macroeconomic and geopolitical uncertainties.
Company Guidance
During the Q3 2024 earnings call for Novanta Inc. (NOVT), the company provided guidance indicating strong operational performance and an optimistic outlook for 2025, despite some short-term challenges. The company reported Q3 revenue of $244 million, reflecting a 10% growth rate, with adjusted EBITDA reaching $57 million, up 9% year-over-year. Novanta's bookings grew by 13%, with major OEM customers confirming new product launches for 2025, expected to contribute an incremental $50 million in revenue. However, the company noted several customer-specific and market challenges leading to a $25 million revenue deferral from Q4 2024 into 2025, particularly affecting the DNA sequencing, semiconductor lithography, and robotic surgery segments. For Q4 2024, Novanta projects revenue between $237 million and $242 million, representing a 12% to 14% growth and organic growth of 2% to 4%. Despite the near-term deferrals, Novanta remains confident in achieving up to 10% organic growth in 2025, driven by new product launches and improvements in the industrial and microelectronics markets.
Strong Third Quarter Performance
Novanta delivered strong third quarter results at the top end of the guidance range with $244 million in revenue, representing a reported growth of 10% and flat growth on an organic basis. Adjusted EBITDA was $57 million, growing 9% year-over-year.
Bookings Growth
Bookings grew 13% year-over-year, with major OEM customers confirming 2025 new product launches. The medical solutions segment saw a book-to-bill of 1.04, and bookings were up 50% year-over-year.
Strategic Growth Metrics
Design wins grew by greater than 20% in the third quarter versus the prior year. New product launches are scheduled to increase by more than 50% in 2024 compared to 2023.
Medical Solutions Segment Growth
The medical solutions segment experienced reported revenue growth of 24% year-over-year. Adjusted gross margins in this segment increased by approximately 60 basis points year-over-year.
---
Novanta (NOVT) Earnings, Revenues Date & History
The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
NOVT Earnings-Related Price Changes
Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Nov 05, 2024
$174.17
$164.67
-5.45%
Aug 06, 2024
$156.50
$170.19
+8.75%
May 07, 2024
$161.14
$161.84
+0.43%
Feb 28, 2024
$157.31
$167.45
+6.45%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Novanta Inc (NOVT) report earnings?
Novanta Inc (NOVT) is schdueled to report earning on Feb 26, 2025, TBA Not Confirmed.
What is Novanta Inc (NOVT) earnings time?
Novanta Inc (NOVT) earnings time is at Feb 26, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.